United States

People: Neurocrine Biosciences Inc (NBIX.OQ)

NBIX.OQ on NASDAQ Stock Exchange Global Select Market

18 Aug 2017
Change (% chg)

$-0.97 (-1.83%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Sherwin, Stephen 

Dr. Stephen A. Sherwin, M.D., serves as an Independent Director of Neurocrine Biosciences Inc., since April 1999. He currently divides his time between advisory work in the life science industry and patient care and teaching in his specialty of medical oncology. He is a Clinical Professor of Medicine at the University of California, San Francisco, and a volunteer Attending Physician in Hematology-Oncology at San Francisco General Hospital. Dr. Sherwin currently serves on the Board of Directors of Aduro Biotech, Inc., Biogen Inc., Rigel Pharmaceuticals, Inc., and Verastem, Inc. Previously Dr. Sherwin served on the Board of Vical Incorporated from 2013 to 2015 and was Chairman and Chief Executive Officer of Cell Genesys, Inc., a cancer immunotherapy company, from 1990 until the company’s merger in 2009 with BioSante Pharmaceuticals (now ANI Pharmaceuticals). He was also a co-founder and chairman of Abgenix, Inc., an antibody company which was acquired by Amgen in 2006, and co-founder and Chairman of Ceregene, Inc., a gene therapy company which was acquired by Sangamo Biosciences in 2013. From 1983 to 1990, Dr. Sherwin held various positions in clinical research at Genentech Inc., most recently that of Vice President. Prior to 1983, he was on the staff of the National Cancer Institute. In addition, Dr. Sherwin previously served on the Board of Directors of the Biotechnology Industry Organization from 2001 to 2014 and as its Chairman from 2009 to 2011. Dr. Sherwin holds a B.A. in biology summa cum laude from Yale University and an M.D. from Harvard Medical School, and is board-certified in internal medicine and medical oncology.

Basic Compensation

Total Annual Compensation, USD 73,625
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 401,700
Fiscal Year Total, USD 475,325

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --